University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

8-25-2022

Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals
Age-Dependent Alterations in the 5XFAD Mouse Model of
Alzheimer's Disease
He N. Xu
Sarah Gourmaud
Allison Podsednik
Xiaofan Li
Huaqing Zhao

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Medicine and Health Sciences Commons

Authors
He N. Xu, Sarah Gourmaud, Allison Podsednik, Xiaofan Li, Huaqing Zhao, Frances E. Jensen, Delia M.
Talos, and Lin Z. Li

H
OH
OH

metabolites

Article

Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals
Age-Dependent Alterations in the 5XFAD Mouse Model of
Alzheimer’s Disease
He N. Xu 1, * , Sarah Gourmaud 2 , Allison Podsednik 1 , Xiaofan Li 2 , Huaqing Zhao 3 , Frances E. Jensen 2 ,
Delia M. Talos 2, * and Lin Z. Li 1, *
1

2

3

*

Citation: Xu, H.N.; Gourmaud, S.;
Podsednik, A.; Li, X.; Zhao, H.;
Jensen, F.E.; Talos, D.M.; Li, L.Z.
Optical Redox Imaging of Ex Vivo
Hippocampal Tissue Reveals
Age-Dependent Alterations in the
5XFAD Mouse Model of Alzheimer’s
Disease. Metabolites 2022, 12, 786.
https://doi.org/10.3390/
metabo12090786

Britton Chance Laboratory of Redox Imaging, Department of Radiology, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA 19104, USA
Department of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA 19104, USA
Center for Biostatistics and Epidemiology, Department of Biomedical Education and Data Science, Temple
University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA
Correspondence: hexu2@pennmedicine.upenn.edu (H.N.X.); talosd@pennmedicine.upenn.edu (D.M.T.);
linli@pennmedicine.upenn.edu (L.Z.L.)

Abstract: A substantial decline in nicotinamide adenine dinucleotide (NAD) has been reported
in brain tissue homogenates or neurons isolated from Alzheimer’s disease (AD) models. NAD,
together with flavin adenine dinucleotide (FAD), critically supports energy metabolism and maintains
mitochondrial redox homeostasis. Optical redox imaging (ORI) of the intrinsic fluorescence of
reduced NAD (NADH) and oxidized FAD yields cellular redox and metabolic information and
provides biomarkers for a variety of pathological conditions. However, its utility in AD has not been
characterized at the tissue level. We performed ex vivo ORI of freshly dissected hippocampi from a
well-characterized AD mouse model with five familial Alzheimer’s disease mutations (5XFAD) and
wild type (WT) control littermates at various ages. We found (1) a significant increase in the redox
ratio with age in the hippocampi of both the WT control and the 5XFAD model, with a more prominent
redox shift in the AD hippocampi; (2) a higher NADH in the 5XFAD versus WT hippocampi at the
pre-symptomatic age of 2 months; and (3) a negative correlation between NADH and Aβ42 level, a
positive correlation between Fp and Aβ42 level, and a positive correlation between redox ratio and
Aβ42 level in the AD hippocampi. These findings suggest that the ORI can be further optimized to
conveniently study the metabolism of freshly dissected brain tissues in animal models and identify
early AD biomarkers.
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1. Introduction

with regard to jurisdictional claims in

Alzheimer’s disease (AD) is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline. The distinct neuropathological features
identified in AD patients include β amyloid (Aβ) plaques, neurofibrillary tau tangles (NFT),
and pronounced neuronal loss, leading to brain atrophy. Furthermore, multiple metabolic
abnormalities, including glucose hypometabolism, lipid dysregulation, alterations of the tricarboxylic acid (TCA) cycle, impaired mitochondrial oxidative phosphorylation (OXPHOS)
activities, and increased oxidative stress have been identified in AD brains [1–8]. While it
is still unclear how these metabolic abnormalities contribute to AD pathology, emerging
evidence shows that metabolic alterations precede the appearance of amyloid plaques and
cognitive decline [2,6,9,10], suggesting that metabolic alterations may represent an early
event in AD progression.
Nicotinamide adenine dinucleotide (NAD, including the oxidized form NAD+ and the
reduced form NADH) and flavin adenine dinucleotide (oxidized form FAD and reduced
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form FADH2 ) are essential co-enzymes for the TCA cycle and the electron transport chain
(ETC). FAD is an electron acceptor, similar to NAD+ in its action. By binding to proteins,
they critically support cell energy metabolism and maintain mitochondrial redox homeostasis. NAD redox sites are critical control sites for metabolic shifts in neurons for aging and
AD mouse models [11]. NAD deficiency and the resulting alteration of the NAD redox status have been previously associated with aging and neurodegenerative declines in culture
models [9,11–14]. A more oxidized redox status (i.e., a higher FAD/NADH ratio) has been
observed in cultured hippocampal and cortical neurons isolated from 4 month 3xtg-AD
mouse brains, prior to increased reaction oxygen species (ROS) and oxidative stress that
promotes neurodegeneration at 10 months of age [9,15]. In AD mouse models, brain NAD+
deficiency was associated with compromised cellular bioenergetics, which may contribute
to AD pathogenesis, as supplementation with NAD precursors at a young age mitigates
neuropathology and/or neurobehavior deficits [16–21]. Similarly, a deficiency in brain
NAD+ levels was implicated in the symptomatic stage of AD patients [13]. However, the
NAD redox status during AD progression has not been systematically characterized at the
tissue level. Both NADH and FAD are intrinsically fluorescent, and their fluorescent intensities indicate the physiological status of cells [22]. Hence, alterations in NADH and/or
FAD contents may indicate pathological conditions.
The optical redox imaging (ORI) technique measures the intrinsic fluorescence intensities of cellular NADH and FAD-containing flavoproteins (Fp). The redox ratio
Fp/(NADH+Fp) is sensitive to mitochondrial redox status, cellular metabolism, and oxidative stress [22–29]. Here, we report a new application of a convenient and quick quantitative
ORI technique to image freshly dissected mouse hippocampal sections ex vivo. By using a
wide-field fluorescence microscope to acquire NADH and Fp intensities, we characterized
the redox status of the hippocampus of a well-characterized AD mouse model with five
familial Alzheimer’s disease mutations (5XFAD) and wild type (WT) control littermates at
various ages spanning the full range of the course of the disease.
2. Materials and Methods
2.1. Animals and Brain Tissue Dissection
2.1.1. Mice
A total of 21 heterozygous 5XFAD (Tg6799 line) mice (7 male, 14 female) and 21 wildtype
(WT) littermates (7 male, 14 female) were used for this study (Supplemental Tables S1 and S2).
Mice were originally obtained from the Jackson Laboratory (MMRRC stock #34840, Bar
Harbor, ME, USA) and maintained on a mixed B6SJL genetic background. The 5XFAD
transgenic mice carried five mutations seen in patients with the genetic familial form of the
disease: the human APP gene with the Swedish K670N/M671L, Florida I716V, and London
V717I mutations, and the human PSEN1 gene with M146L and L286V mutations, under
the control of the Thy1 promoter [30]. Genotyping was performed according to Jackson
Laboratory’s instructions, and was consistent with our previous reports [31]. Animals
were sacrificed between 1.2 and 14 months of age (see Supplemental Tables S1 and S2 for
details). For age-specific ORI analyses, animals with their hippocampal sections subjected
to ORI (n = 21/genotype) were grouped as follows: 2 months (mean 1.83 ± 0.52, range
1.2 to 2.5 months), 3.5 months, 7 months (mean 7.17 ± 0.59, range 6.5–8 months), and
14 months. There was no significant difference in average mouse age between the WT
control and 5XFAD model within each age group. Hippocampal sections from 5XFAD mice
were subjected to Aβ42 assay. All animal procedures were approved by and made in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC)
Office of Animal Welfare of the University of Pennsylvania, Philadelphia, PA, USA.
2.1.2. Mouse Hippocampal Tissue Preparation
After cervical dislocation without anesthesia, mice were decapitated followed by
immediate hippocampus extraction, which was completed within ~1 min. One portion of
the right hippocampus (sagittal cut, ~1 mm) was immediately placed in a glass-bottom
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dish (14 mm diameter of glass, Cellvis, D35-14-1.5-N) filled with 1 mL LCIS+ solution (i.e.,
Live Cell Imaging Solution (Invitrogen™, Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with 22 mM glucose) for redox imaging, whereas the remaining portion was
immediately frozen and used for Aβ42 measurement. The time of dissection was recorded
for each specimen. After extraction of all hippocampi for the day (typically 5–7 mice), fresh
hippocampal samples in glass-bottom dishes were immediately taken to the imaging site
for ORI, which started on average ~35 min after dissection.
2.2. ORI of Fresh Hippocampal Tissue and Data Processing
The cut plane of hippocampal samples was tile-imaged with a wide-field microscope
(EVOS FL Auto Imager) in the order they were extracted from the mice. The DAPI and
GFP filters (excitation and emission windows, as previously described [32]), a 4 × objective
(2343 × 1849 µm2 per field of view), and a 14-bit depth mono-camera were employed
to acquire the images, which were then photo stitched. The time when imaging started
for each specimen was also recorded. Each specimen was imaged multiple times over an
approximate 2 h period. To prevent tissue from moving while being imaged, a clean onecent coin was partially laid on top of the ~1 mm thick tissue section, with the larger portion
of the coin resting on the plastic part of the dish bottom to reduce potential weight-induced
stress on the tissues.
To perform a metabolic modulation experiment, small and thin tissue slices (<1 mm,
n = 5/genotype) were sliced off from two hippocampal sections in the 2-month-old mouse
group after redox imaging acquisitions were performed for these sections. Mitochondrial oxidative phosphorylation uncoupler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP, 30 µM final concentration) was carefully added to the medium, and the redox signals
were acquired before and immediately after FCCP addition. Rotenone and antimycin A
(ROT/AA, 10 µM/6 µg/mL, final concentrations) were then added to the dishes, followed
by immediate imaging [25,26,33,34]. The interval between each drug administration and
imaging was <1 min. All drugs were purchased from Millipore Sigma and reconstituted in
DMSO. The stock aliquots were stored in a −80 ◦ C freezer.
The images were processed and quantified using ImageJ and/or Matlab. A tissue-free
area was chosen as the background of the image for the NADH or Fp channels. The region
of interest (ROI) was drawn along the tissue area. The net global mean value for NADH or
Fp was then calculated by subtracting their respective background. These net mean values
were then used to quantify the redox ratio Fp/(NADH+Fp) of a specific tissue specimen.
Within each age group, data acquired at different times were corrected to the time when the
first data were acquired (~35 min after dissection), using the relationship between redox
signals and elapsed time.
2.3. Aβ42 Quantification
The frozen portion of the dissected hippocampi from twenty 5XFAD mice were homogenized on ice, and then used for quantification of the soluble human Aβ42 by ELISA
at room temperature, according to the manufacture’s manual (Thermo Fisher Scientific,
Waltham, Massachusetts, USA; Cat. # KHB3441). Briefly, 50 µL aliquots of tissue samples
and reference standards (0–1000 pg/mL) were loaded into wells in the supplied 96-well
plate, and 50 µL of Hu Aβ42 detection antibody solution was added to each well. The
mixtures were incubated for 3 h with shaking, then the plate was washed four times with
supplied 1 × wash buffer. A total of 100 µL anti-rabbit IgG HRP was added to each well
and incubated for 30 min, then the plate was washed four times with 1 × wash buffer. A
total of 100 µL stabilized chromogen was added to each well and incubated for 30 min in
the dark. A total of 100 µL stop solution was added to each well, and the plate was read at
450 nm absorbance with a microplate reader. The Aβ42 levels were calculated by fitting
to a standard curve using Microplate Manager (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) and were expressed in pg/mL.

e1
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2.4. Statistical Analysis
GraphPad Prism 9 was used for the statistical analyses. The mean values were compared between the WT and 5XFAD groups, using an unpaired Student’s t-test and assuming unequal variance, or using one-way ANOVA with Tukey correction for multiple
comparisons. When appropriate, the slopes between the WT and 5XFAD groups were also
compared using a linear regression model. p < 0.05 was considered statistically significant.
3. Results
3.1. Confirmation of Redox Signals in Hippocampal Tissue
The schematic for all imaging experiments for this study is shown in Figure 1. We
conducted a metabolic modulation experiment to confirm the redox signals and metabolic
viability of freshly dissected hippocampal slices [25,33,34]. As expected, after adding
mitochondrial oxidative phosphorylation uncoupler FCCP to the culture medium, we
immediately observed a ~40% NADH decrease and a ~20% increase in the redox ratio,
without a significant change in Fp signals for both the WT and 5XFAD groups (Figure 2).
Subsequently, by adding rotenone and antimycin A, which inhibit mitochondrial complex I
and III, respectively, we observed an immediate recovery of NADH signal and a decreased
redox ratio. These changes indicated that the tissues were viable and confirmed that ORI
detected the redox signals in the hippocampal slices.

Figure 1. The schematic for ex vivo optical redox imaging of hippocampal slice. Approximately
1 mm thick sagittally cut hippocampal section from a freshly dissected right hippocampus was placed
in a 35 mm glass-bottom dish containing imaging solution immediately after slicing. Before imaging,
the hippocampal slice was immobilized by a penny coin, with majority of the coin weight resting
on the plastic part of the dish bottom. The cut plane was tile-imaged with an inverted wide-field
fluorescence microscope equipped with proper optical filters, a 4 × objective lens with a field of view
of 2343 × 1849 µm2 . The raw images of NADH and Fp were processed and quantified using ImageJ,
and subsequently underwent further analyses (see Materials and Methods for details).

Metabolites 2022, 12, x FOR PEER REVIEW

of 2343 × 1849 µ m2. The raw images of NADH and Fp were processed and quantified using ImageJ,
and subsequently underwent further analyses (see Materials and Methods for details).5 of 12

A

B

WT
Baseline

FCCP

ROT/AA

✱✱✱

✱✱

✱

1.0

0.5

0.0

NADH

Fp

5XFAD
1.5

Baseline
✱✱
✱✱

FCCP

ROT/AA
✱✱

✱

✱✱

1.0

0.5

0.0

Fp/(NADH+Fp)

NADH

Fp

Fp/(NADH+Fp)

Figure 2. Redox responses of ~1 mm thick hippocampal slices from 2-month-old wild type (A) and

Figure 2. Redox responses of ~1 mm thick hippocampal slices from 2-month-old wild type (A) and
5XFAD (B) mice to the metabolic modulator FCCP followed by rotenone + antimycin A (ROT/AA).
5XFAD (B) mice to the metabolic modulator FCCP followed by rotenone + antimycin A (ROT/AA).
Bars represent normalized mean ± SE (before and after drug administration for the same field of
Bars represent normalized mean ± SE (before and after drug administration for the same field of
view, n = 5 slices/genotype). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (paired t-test).
view, n = 5 slices/genotype). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (paired t-test).
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3.3. Relationship between the Redox Indices and Age
To determine whether and how the redox indices (NADH, Fp, and the redox ratio)
changed as mice aged, we quantified the hippocampal redox indices from 21 WT and
21 5XFAD mice aged 1.2 to 14 months (see Supplementary data tables for details). These
mice were grouped into four age groups: 2, 3.5, 7, and 14 months. These ages are related
to their neuropathological and phenotypical characterizations: amyloid-β accumulation
from 1.5–2 months; behavioral and synaptic impairment from 4 months; synaptic and
neuronal loss from 7 months onward. The within group analyses revealed a ~21% increase
in NADH signal in the hippocampi of 5XFAD mice compared to their WT littermates for
the 2 month group (p < 0.05, Figure 4A), no significant change in Fp (Figure 4B), and a trend
in a more reduced redox ratio (p = 0.13, Figure 4C). For the 3.5 mo. group, there was no
significant difference in any of the redox indices between the WT and AD hippocampi (data
not shown). For the 7 month group, the 5XFAD hippocampi showed a ~41% higher Fp
content (p = 0.002) and a ~24% higher redox ratio (p = 0.0007) relative to the WT, but there
were no significant NADH differences (p = 0.6) (Figure 4D–F). Only two 5XFAD samples
were imaged in the 14 month group (due to an unexpected death of a 5XFAD mouse before
this experiment); therefore, no statistical analysis was performed for this group.

J
2400

2000

2000

2000

1600

1600

1600

1200

1200

1200

800

✱

WT

800

5XFAD

B

WT

800

5XFAD

E

WT

5XFAD

M

K

N

L

O

5XFAD

H
1000

✱✱

800
Fp (a.u.)

NADH (a.u.)

G
2400

2400

WT

NADH (a.u.)

D

14 months

Fp/(NADH+Fp)

A

7 months

NADH (a.u.)

2 months

Fp/(NADH+Fp)

Figure 4

600
400
200
0
WT

C 0.4

F

0.4

✱✱✱

I

0.4

0.3

0.3

0.3

0.2

0.2

0.2

0.1

0.1

0.1

0.0

0.0
WT

5XFAD

WT

5XFAD

5XFAD

0.0

WT

5XFAD

Figure 4. The relationship between redox indices and age in the hippocampi of 5XFAD and wild
type mice. Quantified hippocampal redox indices in 2 month (A–C), 7 month (D–F), and 14 month
(G–I) groups are graphed with mean ± SD (*, p < 0.05; **, p < 0.01; ***, p < 0.001) and individual
mouse values (dots). Linear regressions were performed to represent the trend of time courses of the
redox indices (each dot represents the hippocampus from an individual mouse) for WT (J–L) and
5XFAD (M–O).
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Consistent with these results, the linear regression of NADH, Fp, and the redox ratio
with age (Figure 4G–L) showed no significant correlation between NADH and age in the
WT hippocampi; however, it did show a significant linear NADH decrease in the 5XFAD
hippocampi with advancing age (p = 0.0078). Furthermore, although both Fp and the redox
ratio increased linearly with age in both the WT control and 5XFAD model, the rate of
increase was larger in 5XFAD mice (Figure 4K). Specifically, the 5XFAD hippocampi showed
a significantly larger Fp slope than that of the WT hippocampi (45 versus 27 a.u./month,
p = 0.012). Similarly, the redox ratio slope for the 5XFAD hippocampi was more than twofold greater than that of the WT mice (p < 0.001). We did not observe any difference in the
redox indices between male and female mice in either the 5XFAD or WT group.
3.4. Correlations between the Redox Indices and Aβ42 Level in the Hippocampi of AD Mice
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mice were as young as 1.5 months. As expected, Aβ42 levels increased as mice aged [30]
despite the large variations among individuals, and there was a positive linear correlation
between Aβ42 level and age with high significance (Figure 5A). We further performed
linear regression to identify possible correlations between the redox indices and Aβ42
level. We found there was a negative linear correlation between Aβ42 and NADH (p = 0.02;
Figure 5B), and a positive linear correlation between Aβ42 and Fp (p < 0.0001; Figure 5C), as
well as Aβ42 and the redox ratio p < 0.0001; Figure 5D). We did not observe any significant
sex difference in either age or Aβ42 level in 5XFAD mice.
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Figure 5

Figure 5. Relationships between Aβ42 level (pg/mL) and redox indices in the 5XFAD hippocampi.
(A) a positive linear correlation between Aβ42 level and mouse age; (B) a negative linear correlation
between NADH and Aβ42 ; (C) a positive linear correlation between Fp and Aβ42 ; (D) a positive
linear correlation between the redox ratio and Aβ42 .

4. Discussion
4.1. The Hippocampal ORI Measures Differentiate Normal Aging from AD
We performed optical redox imaging to investigate the NAD redox status in freshly
dissected hippocampi from both WT and 5XFAD mice spanning from ~1 to 14 months of age.
The 5XFAD model has been demonstrated to recapitulate key pathological features of AD
patients, such as progressive amyloid pathology, neuronal loss, and cognitive dysfunction,
as well as gene expression patterns and pathway activities similar to human late-onset
AD [35]. The 5XFAD model exhibits intraneuronal soluble Aβ42 accumulation starting at
1.5 months of age before plaques form, and the appearance of cognitive dysfunction around
4–5 months, when there is extensive amyloid pathology [30,36]. Temporal gene profiling of
the 5XFAD neocortex and hippocampus also showed a clear region-specific shift in gene
expression patterns between 1 month (pre-symptomatic stage) and 4 months (prodromal
stage), with the most dramatic changes occurring from 4 months onwards, including
regulatory genes involved in inflammatory and immune processes [37]. In parallel with
these established features, we observed significant age-dependent oxidized redox shifts in
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the hippocampus of both 5XFAD and WT mice over the 2–14 month period, with a larger
shift in 5XFAD than in WT mice.
NAD+ deficiency has previously been described in normal brain aging and neurodegenerative disorders, including AD in various models [13]. Owing to the intrinsic
fluorescence properties of NADH, aging induced NADH changes have been studied by
optical fluorescence methods. For example, an in vitro study measuring NADH and FAD
fluorescence intensity in cultured hippocampal and cortical neurons isolated from 3xTg-AD
and non-transgenic control mice at various ages showed that NADH intensity continuously increased between 2 to 11 months, with levels significantly lower in the 3xTg-AD
versus the non-transgenic control neurons from 2 months onwards [9]. The same study
also showed that the redox ratio NADH/FAD followed the same trend as that of NADH
in non-transgenic control neurons between 2–21 months, whereas this ratio continued
to decline from 2 months onwards in 3xTg-AD neurons. In our study, we found that
the hippocampal NADH level was significantly higher in 2 month 5XFAD mice than in
age-matched WT littermates. While we did not observe a significant NADH change with
age in WT hippocampal tissue, the hippocampal NADH linearly decreased with age in
5XFAD mice. Furthermore, we found a larger age-dependent increase in the redox ratio
Fp/(NADH+Fp), i.e., a shift to a more oxidized state due to both decreasing NADH and
increasing Fp in the 5XFAD hippocampi, consistent with the aforementioned report on
neurons isolated from 3xTg-AD mice, showing a continuous decrease in the NADH/FAD
ratio with age [9]. Note that their redox ratio defined as NADH/FAD is inversely related to
our definition Fp/(NADH+Fp). Another study of isolated mouse hippocampal neurons,
which employed a fluorescence lifetime imaging microscopy technique, demonstrated
that it was the free NADH that significantly decreased due to normal aging and, more so,
due to AD (3xTg-AD mouse); additionally, there was also a significant shift from free to
protein-bound NADH [14]. However, there are no studies to date reporting that NADH
changes at the tissue level in the mouse brain of AD models by any imaging modality.
4.2. The ORI Measures Correlate with Hippocampal Aβ42 Level in 5XFAD Mice
Since Aβ level in the 5XFAD model indicates AD progression, the significant associations between the redox indices and Aβ42 levels we observed support the notion that
hippocampal NAD redox status is indicative of AD pathology. Oxidative stress is associated
with damaged Aβ peptide and contributes to AD progression [38]. Furthermore, oxidative
stress was shown to be one of the biological processes associated with differentially expressed proteins in 5XFAD and WT mice at the age of 4 months [39]. We previously reported
that a higher redox ratio correlates with higher reactive oxygen species (ROS), generated
by oxidative insults [25,26,28], and higher oxidative stress in inflamed rhesus macaques
brains [29]. As NAD redox abnormality occurs earlier than ROS-induced oxidative stress
on macromolecules and is an upstream event in isolated neurons from AD mice of various
ages [9,15], it suggests that our observation that a decreased NADH, an increased Fp, and a
more oxidized redox status correlated with the increase of Aβ in the 5XFAD hippocampi
is consistent with the understanding that oxidative stress underlies AD development in
5XFAD mice. It remains to be tested in the future whether the alterations of ORI measures
in the early stage can predict the disease progression and severity in the late stages of AD.
4.3. Limitations of Our Study and Open Questions
There are several technical limitations in the study. First, we took a low-resolution
imaging approach with a wide-field fluorescence microscope. This low-cost and convenient
approach is sufficient for global averaging analysis to differentiate between AD and WT
models, but it does not provide finer details regarding the redox distribution within
tissue. An alternative approach is to employ an upright two-photon microscope that
provides much higher resolution for imaging ex vivo tissue in investigating regional and
cellular redox changes within brain tissues, as we observed in freshly dissected mouse
leg muscles [32]. Second, as all tissue glues tested have strong fluorescence in the NADH
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channel, we had to alternatively place a coin to immobilize the tissue section. It is unclear
whether this could put the tissue under significant mechanical stress, despite most of the
coin weight being placed on the plastic portion of the dish bottom (Figure 1). However,
since both WT and 5XFAD tissues were imaged the same way, such mechanical stress
should not differentially affect their metabolism. Third, ORI cannot differentiate between
NADH and NADPH signals; therefore, the NADH measures reported here include the
contributions by both fluorophores, but NADPH signal is much weaker in brain tissues [40].
In addition, the optically determined redox ratio may or may not reflect the NAD+/NADH
redox potential measured by other means. The optical redox ratio FAD/(NADH+FAD)
was demonstrated to be linearly proportional to NAD+ /(NADH+NAD+ ), determined by
liquid chromatography coupled with mass spectroscopy (LC/MS-MS) in differentiating
stem cell cultures [41] or precancerous tissues [42]. In contrast, breast cancer cells that
have a compromised NAD+ synthesis demonstrated a reductive shift in NAD+ /NADH
ratio, as measured by biochemical assay [43], but an oxidative shift in the optical redox
ratio [27]. Therefore, it is likely that, under certain conditions, the positive linear correlation
between NAD+ /(NADH+NAD+ ) and the optical redox ratio may not hold. In this study,
we found that the optical redox ratio increased with age and, more so, with AD progression
in the hippocampal tissues. In comparison, the NAD+ /NADH ratio measured in vivo by
phosphorous-31 magnetic resonance spectroscopy in the occipital lobe of normal human
brains were reported to decrease with age [44]. This apparent discrepancy in the age
trend for redox ratios might be interpreted by the fact that the optical redox ratio has two
redox sensors: the NADH and FAD. Thus, the optical redox ratio Fp/(NADH+Fp) is a
parameter that can be affected by both the bioenergetics and oxidative stress. With aging,
NAD+ /NADH may decrease, reflecting lower bioenergetics, whereas the optical redox
ratio may increase due to increased oxidative stress. Nevertheless, more investigations are
needed to further understand the biological basis of the optical redox ratio.
Lastly, the primary goal of this study was to explore whether optical redox imaging
can detect aging effects and reveal metabolic differences between normal aging and ADinduced metabolic abnormality. Potential sex differences were not part of the original
study design, but we tested it during data processing. Studies of sex difference with this a
priori hypothesis should be considered in the future with a more balanced research design,
including even animal numbers. In addition, subsequent studies should explore potential
changes in NADH, Fp, and the redox ratio in other brain regions, such as the cortex.
5. Conclusions
Employing a wide-field fluorescence microscope, this study examined the utility
of ex vivo optical redox imaging of freshly dissected hippocampal tissue sections from
5XFAD and WT mice to study Alzheimer’s disease in comparison with normal aging. The
ORI method reported here detected significant redox differences between the AD and
normal hippocampi. To the best of our knowledge, our study provides the first imaging
measurements of NADH, Fp, and the redox ratio at the tissue level of AD models at various
ages. Our findings suggest that the ORI can be further optimized to conveniently study
the metabolism of freshly dissected brain tissues in animal models. Furthermore, NADH
abnormality could be an early event of AD; thus, further investigation of its role in disease
pathology and its potential as an early biomarker for AD is warranted.
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